2002

Jeffrey Bartlett, PhD

Callimune, Inc. Vice President, Research & Development

Research Focus: Gene Therapy for Ovarian Cancer

Cancer Type: Ovarian Cancer

Award: Young Investigator

Dr. Bartlett has continued his research on the AAV virus in creating vectors for use in gene therapy. His work in developing these vectors provides promising opportunities for the future of ovarian cancer and other cancer treatment as an alternative method of delivering specific genetic information to cancer cells. Dr. Bartlett has also been working on engineering a resistance to the HIV-1 infection through the use of gene therapy. He and a team of researchers have developed and studied an anti-HIV lentiviral vector capable of generating cellular resistance to multiple strains of HIV in two different ways. Many animals treated with the vector-modified cells had no detection of the HIV virus in the bloodstream, whereas it was easily detected in the control group not treated with the cells. Dr. Bartlett’s research on vectors is likely to progress the field of gene therapy treatment for both cancer, HIV, and potentially other diseases as well.

Ovarian cancer is one of the most common and frequently life-threatening malignancies affecting women in the U.S. today: about 25,000 new cases will be diagnosed with the disease this year and over 15,000 women will die from it. Delivering therapeutic genes efficiently and precisely, so that they reach only the targeted cancer cells, is crucial to success. My group has developed a means of delivering therapeutic genes to a specific population of cells in laboratory experiments. By rearranging the genetic structure of AAV, a common human virus, we have created a class of molecular Trojan horse viruses, known as vectors, from the Latin “to carry”. These vectors are aimed at ovarian cancer cells via key sequences in the virus shell that allows it to infect only cells in the body displaying a particular marker that is restricted to cancer cells. We are now testing the Trojan horse system’s ability to cure ovarian cancer in laboratory animals. If these studies are successful, this research will help pave the way for clinical trials in women with ovarian cancer and may lead to a new approach to this deadly disease.

At time of the Award: The Research Institute at Nationwide Children’s Hospital Columbus, OH

Assistant Professor, Pediatrics, Molecular Virology, Immunology and Medical Genetics

Return to Fellows List